Summary
The product Aromasin Exemestane 10mg, manufactured by Unique Pharma, underwent independent testing to verify its authenticity and potency. The sample, identified by batch number UN66337 exp 05/2027, was submitted by the reseller Opitropin.EU and analyzed by Janoshik Analytical, a laboratory specializing in pharmaceutical quality control. The analysis measured the presence of Exemestane, with a concentration of 12.23 mg, exceeding the labeled claim of 10 mg by 22.3%.
The testing process commenced on 18 June 2024, with the sample received on 20 June 2024, and the analysis completed on 21 June 2024. While the results confirm the product contains more than the stated dosage, it is crucial to consider that reseller-submitted samples may represent high-quality batches that do not necessarily reflect overall product consistency. Independent third-party testing remains essential to validate these findings comprehensively. This report serves as an educational resource to promote harm reduction and informed decision-making.
Detailed Report
Product Overview
- Manufacturer: Unique Pharma
- Product Name: Aromasin Exemestane 10mg
- Active Ingredient: Exemestane
- Batch Number: UN66337 exp 05/2027
- Expiration Date: May 2027
- Delivery Method: Oral
Sample Acquisition and Testing
- Task Number: #44219
- Testing Ordered: 18 June 2024
- Sample Received: 20 June 2024
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: Opitropin.EU (Reseller)
- Analysis Paid For By: Opitropin.EU
Testing Results
- Specification: 10 mg (as stated on the label)
- Measured Concentration: 12.23 mg
- Accuracy: 122.3% (22.3% above the label claim)
- Variance: +22.3%
Verification Details
- Verification URL: www.janoshik.com/tests/44219_8QXKJ2R3N5PB
- Originally Published: https://thinksteroids.com/community/posts/3118518/
Evaluation of Reseller-Submitted Testing
This analysis confirms that the tested product exceeds its labeled claim, raising questions about dosage consistency. Since the sample was submitted and funded by the reseller Opitropin.EU, there is a possibility that high-quality batches were selectively chosen for analysis. To ensure a comprehensive understanding of the product’s consistency, further third-party testing across multiple batches is recommended.
Conclusion
The analysis of Aromasin Exemestane 10mg confirms a higher-than-expected measured concentration of 12.23 mg, indicating an overdose. This suggests strong quality control for this batch; however, the significant variance highlights the need for further independent testing to ensure consistent dosing across production batches. This report aims to support educational and harm reduction efforts, helping consumers make informed choices.
Disclaimer
This report is published for educational and harm reduction purposes. Reseller-submitted testing may introduce inherent biases; however, it still provides useful data when critically assessed alongside third-party or independent results. Readers are encouraged to use this information responsibly.
